170
Participants
Start Date
August 19, 2019
Primary Completion Date
November 9, 2020
Study Completion Date
October 1, 2021
Ocrelizumab (CinnaGen, Iran)
Ocrelizumab (CinnaGen, Iran) will be administered via intravenous (IV) infusion.
Ocrelizumab (Roche, Switzerland)
Ocrelizumab (Roche, Switzerland) will be administered via intravenous (IV) infusion.
Qaem International Hospital, Rasht
Qaem Hospital, Mashhad
Golestan Hospital, Ahvāz
Bouali Hospital, MS Clinic, Sari
Sina Hospital, Hamadan
Ayatollah Kashani Hospital, MS Clinic, Isfahan
Shafa Hospital, Kerman
Imam Reza Hospital, Kermanshah
Dr. Nikseresht's office, Shiraz
Namazi Hospital, Shiraz
Imam Reza Hospital Department of Neurology, Tabriz
Amir Alam Hospital, Tehran
Imam Hossein Hospital, MS Clinic, Tehran
Imam Khomeini Hospital, Tehran
Sina Hospital, MS Research Center, Tehran
Lead Sponsor
Cinnagen
INDUSTRY